Cagrilintide and Semaglutide (CagriSema)
What is CagriSema, how much more weight does it lose than semaglutide alone, and can you recreate it with grey market vials?
Reviewed by the amino101 editorial team. .
Also searched as Cagri Sema, CagriSema stack, amylin GLP-1 combination, cagrilintide semaglutide blend.
Cagrilintide is a long-acting analogue of the hormone amylin that reduces appetite through a different pathway than GLP-1 drugs. Alone it produced about 11 percent weight loss in Phase 2; paired with semaglutide as CagriSema it reached about 20 percent in Phase 3.
Semaglutide is a once-weekly GLP-1 receptor agonist that cuts appetite and slows digestion, producing average weight loss around 15 percent in trials. It is the molecule behind the Ozempic and Wegovy brand names.
Cagrilintide and semaglutide are combined because they drive satiety through two different systems. Semaglutide is a GLP-1 receptor agonist, the molecule in Ozempic and Wegovy, with about 15 percent average weight loss at 2.4 mg over 68 weeks in STEP 1. Cagrilintide is a long-acting amylin analog that works through brainstem amylin receptors, producing about 11 percent loss on its own at 4.5 mg weekly in phase 2. Novo Nordisk put the two together as CagriSema, and the REDEFINE phase 3 trials reported roughly 20 to 23 percent weight loss at 68 weeks depending on the population and the analysis, more than either component alone. Those are sponsor-reported figures. REDEFINE 1 has been published, but the combination is not approved anywhere as of October 2026 and regulatory review is pending.
This is the only stack on the site with phase 3 evidence behind the combination itself. It is also one of the riskier ones to copy at home, because the grey market version means two unverified vials, two separate titrations and a stacked GI load. This page covers what the trials did, how community users approach adding cagrilintide to semaglutide they already take, and why slow escalation is the whole game. Semaglutide is an approved drug; cagrilintide is not. Educational only.
Why people combine Cagrilintide and Semaglutide
GLP-1 receptors in the hypothalamus and brainstem reduce hunger and the reward value of food. Amylin receptors in the area postrema produce satiety, slow gastric emptying and suppress glucagon through largely different neurons. Because the receptors and circuits differ, the signals add rather than compete, which is the rationale Novo tested and which the phase 1b and REDEFINE 1 results support.
In the 20 week phase 1b, cagrilintide plus semaglutide gave about 17 percent loss versus 10 percent for semaglutide alone. REDEFINE 1 reported about 20 percent at 68 weeks in adults with obesity, and REDEFINE 2 about 14 percent in type 2 diabetes with HbA1c reductions. That is short of the 25 percent Novo projected, but clearly above semaglutide's 15 percent in STEP 1.
People who have stalled on semaglutide sometimes respond to adding the amylin pathway. This is mechanistically sound and common in community protocols, but the only trial data started both drugs together; nobody has trialed adding cagrilintide to someone already at a semaglutide plateau. The semaglutide vs tirzepatide page covers the other common answer to a plateau.
It does not make either drug gentler. Nausea, vomiting and under-eating are the main effects of both, and slowed gastric emptying stacks. It does not change what happens when you stop; weight regain should be assumed. And a grey market vial labeled cagrilintide gives none of the quality assurance of the dual-chamber pen used in the trials.
CagriSema dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| Cagrilintide | 0.3 mg start, escalating to 2.4 mg | once weekly | subcutaneous, abdomen or thigh, same day as the semaglutide, separate injection; each step held at least 4 weeks |
| Semaglutide | 0.25 mg start, escalating to 2.4 mg | once weekly | subcutaneous, abdomen, thigh or upper arm, same day each week, with or without food; each step held at least 4 weeks |
Not cycled. The CagriSema trials escalated both drugs in lockstep over 16 weeks to 2.4 mg each and then held that dose through 68 weeks. People adding cagrilintide to semaglutide they already take usually start at 0.3 to 0.6 mg and climb every 4 weeks, holding a step longer whenever nausea or under-eating has not settled. Stopping is a taper over months rather than a cold stop, because appetite and weight return.
- •The CagriSema dose is 2.4 mg of each, reached together. Cagrilintide monotherapy went to 4.5 mg, but that is not the combination dose.
- •Both half-lives are about a week, so each step keeps building for a month. Escalating faster than every 4 weeks stacks nausea before the last step has settled.
- •Injection site reactions were more common with cagrilintide than with semaglutide in the trials. Rotate sites and keep the two injections apart.
- •Protein intake and resistance training matter more here than on semaglutide alone, since larger total loss means more lean mass at risk.
Work out syringe units for any of these in the dosage calculator.
Can you mix Cagrilintide and Semaglutide in one syringe?
In the trials the two were given from a dual-chamber pen as separate injections, never premixed. Community users often draw both into one syringe, which is convenient and untested for stability; the cagrilintide compound page calls separate injections the safer default. There is no copper or pH issue, just no data, and vendors do sell CagriSema-style blends in one vial, which locks the two into a fixed ratio and removes the ability to hold one drug at a step while the other climbs, which is the main reason to keep them separate. The insulin syringe units chart covers drawing two different concentrations.
What to expect, week by week
- Week 1 to 4
Meals feel smaller, snacking drops, some nausea, injection site redness from the cagrilintide. Little weight change at the tolerance doses.
- Week 4 to 12
Appetite suppression firms up as both doses climb. Loss of 1 to 2 pounds a week is typical. Side effects flare briefly after each step.
- Month 3 to 6
Steady loss at the combined dose, GI effects settle. On CagriSema the combined effect is clearly larger than semaglutide alone by now.
- Month 6 to 18
Loss continues toward the 20 percent range reported in REDEFINE 1, with a plateau in the second year. Muscle and protein intake become the focus.
Side effects and cautions
- ▲Nausea and vomiting, worst after each dose increase of either drug
- ▲Injection site redness, itching or lumps, more common with cagrilintide
- ▲Appetite reduced to the point of under-eating and low energy
- ▲Constipation or diarrhea
- ▲Burping, reflux and early fullness
- ▲Headache and fatigue in the early weeks
- ▲Hair shedding a few months into rapid weight loss
- ■Anyone on insulin or a sulfonylurea. Both drugs raise hypoglycemia risk in combination and the other medication usually needs a dose reduction.
- ■A personal or family history of medullary thyroid cancer or MEN2, the semaglutide boxed warning.
- ■Severe or persistent abdominal pain at any point. Pancreatitis is rare, but the UK MHRA issued a safety alert in January 2026 describing it as an infrequent but potentially fatal GLP-1 side effect, and both drugs slow gastric emptying.
- ■Anyone on oral medications with a narrow margin such as warfarin or levothyroxine. Slowed emptying stacks across two drugs and can change absorption.
CagriSema makes sense on paper for someone who has reached the top of semaglutide, has stalled well short of their goal, and understands that adding cagrilintide means a second unapproved, unverified vial and a second titration. The phase 3 data is real and the gain over semaglutide alone is meaningful, roughly 5 percentage points at 68 weeks. But the approved route to that kind of loss already exists: tirzepatide at 15 mg produced about 20 percent in SURMOUNT-1 as a single, branded, lot-tested product. For most people who want more than semaglutide gives, switching to tirzepatide is the simpler, safer path. The grey market CagriSema copy is for people who cannot use tirzepatide or who are already past it, and even then slow escalation and a clinician aware of both drugs are not optional. Anyone on insulin, with a thyroid cancer history, or with a history of pancreatitis has no business doing this. Educational only.
CagriSema: frequently asked
How much weight do you lose on CagriSema?
REDEFINE 1 reported about 20 percent at 68 weeks in adults with obesity, and analyses limited to people who stayed on treatment put it closer to 23 percent. That compares with about 15 percent for semaglutide alone in STEP 1. The figures are sponsor-reported and the combination is not yet approved.
Can I add cagrilintide to semaglutide I am already taking?
That is how most community users do it. The usual approach is to start cagrilintide at 0.3 to 0.6 mg weekly on the same day as the semaglutide and climb every 4 weeks while watching nausea and food intake. The trials escalated both from zero together, so adding it mid-course is untested.
Can you mix cagrilintide and semaglutide in the same syringe?
In the trials they were separate injections from a dual-chamber pen. Community users mix them; stability is untested. Separate injections also let you hold one drug at a step while the other climbs, which matters during titration.
Is CagriSema better than tirzepatide?
The numbers are similar, about 20 percent for both, from different trials in different populations, so no direct comparison exists. Tirzepatide is approved and available as a branded product; CagriSema is not. The semaglutide vs tirzepatide vs retatrutide page covers the approved and late-stage options.
Does cagrilintide work with tirzepatide instead?
Community users do it, and the mechanism argument is the same, but there is zero trial data for that pairing. The cagrilintide page lists it as compatible with the advice to escalate slowly.
What happens when you stop CagriSema?
Appetite returns within weeks and most of the weight comes back within a year, the same pattern seen after stopping semaglutide. A slow taper to a lower maintenance dose is what people use rather than quitting cold. The GLP-1 microdosing article covers the low-dose maintenance idea and its lack of trial support.
Related reading
Weight loss while limiting muscle loss
The two approved GLP-1 drugs went head to head. What does the result mean for you?
Three generations of GLP-1 drugs. What actually separates them?
The triple agonist beats the dual agonist on paper. Is it worth waiting for, or buying early?
GLP-1
GLP-1
Guide
Dosage
First generation versus third. How big is the gap, and what do you give up to close it?
Sources
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 2021
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 2021
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021
- Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). New England Journal of Medicine, 2025